Immunic Raises $400M to Advance First-in-Class Multiple Sclerosis Therapy Toward Commercial Launch
核心洞察
Immunic secured an oversubscribed $400 million private placement led by BVF Partners (搜索) to transition from R&D-focused to commercial-stage operations.
The funding will complete Phase III ENSURE studies of vidofludimus calcium in relapsing multiple sclerosis (搜索), with top-line results expected by year-end.
Vidofludimus calcium represents a first-in-class therapy targeting both neuroprotection via Nurr1 (搜索) activation and inflammation reduction through selective DHODH (搜索) inhibition.
Immunic has completed an oversubscribed $400 million private placement to fund its transition from an R&D-focused organization into a commercial-stage entity, positioning the company to advance its lead multiple sclerosis (搜索) therapy toward regulatory approval and market launch.
The financing round was led by existing investor BVF Partners (搜索) and included participation from Avidity Partners (搜索), OrbiMed (搜索), Trails Edge Capital Partners, TCGX, Vivo Capital and other institutional investors. The funding provides Immunic with resources to operate through late 2027 and execute key clinical and commercial milestones.
Phase III Program Nears Completion
The proceeds will primarily support completion of Immunic's ongoing Phase III ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis (搜索), with top-line results anticipated by the end of this year. The company aims to submit a new drug application in the US by mid-2027 and targets regulatory approval in 2028.
Parallel efforts are focused on preparing for vidofludimus calcium's potential commercialization, including expanding medical and commercial teams. The company plans to launch a Phase III clinical program in primary progressive multiple sclerosis (搜索) later this year, with the trial estimated to require approximately three-and-a-half to four years to complete.
Novel Mechanism of Action
Vidofludimus calcium is designed as a first-in-class therapy that targets both neuroprotection via Nurr1 (搜索) activation and inflammation reduction through selective dihydroorotate dehydrogenase (搜索) (DHODH (搜索)) inhibition. This dual mechanism approach represents a potentially differentiated treatment strategy for multiple sclerosis (搜索) patients.
Financing Structure and Leadership Transition
Under the private placement terms, Immunic agreed to issue 229.1 million pre-funded warrants at $0.873 per warrant, yielding upfront proceeds of $200 million. Investors will also receive warrants for up to an additional 229.1 million shares at the same price for the remaining $200 million. These warrants are set to expire on the earlier of 30 days following public release of Phase III ENSURE data or February 17, 2031.
Leerink Partners served as lead placement agent alongside B Riley Securities, Brookline Capital Markets, Guggenheim Securities, LifeSci Capital, Stifel and William Blair.
"I would like to thank BVF and the other investors in the consortium for joining our journey towards potential regulatory approval of vidofludimus calcium," said Immunic co-founder and CEO Dr. Daniel Vitt.
The company's board will begin searching for a new CEO with multiple sclerosis (搜索) commercial expertise as Dr. Vitt transitions to a new executive role focused on scientific strategy and portfolio advancement, reflecting the organization's evolution toward commercial readiness.